Gene Solutions
Gene Solutions is a biotechnology company based in Ho Chi Minh City, Vietnam, that develops genetic testing services using next-generation sequencing.[1] Founded in 2017, it initially specialised in non-invasive prenatal testing (NIPT) and later expanded into cancer screening tests.[2][3]
The company was established by Nguyen Hoai Nghia (CEO), Nguyen Huu Nguyen, and Giang Hoa.[4] It has been described as the market leader in NIPT in Vietnam.[2][5]
Expansion
Gene Solutions started with prenatal testing in Vietnam and later grew into other Southeast Asian markets.[3] It opened a diagnostics lab and branch in Singapore to serve as a regional centre, and formed partnerships in countries including Thailand, Indonesia, the Philippines, and Malaysia.[2][6]
Funding
Mekong Capital invested $15 million in 2021 through its Mekong Enterprise Fund IV.[4] A follow-on Series B round in 2023 raised $21 million from the same fund to support oncology testing and regional growth.[5]
In November 2025, the company announced plans to raise up to $100 million through a pre-IPO round and a possible 2026 listing, potentially in Singapore or Hong Kong.[1]
Tests and research
Its main prenatal test is triSure, a non-invasive screening for chromosomal abnormalities.[2]
For cancer detection, Gene Solutions offers SPOT-MAS, a multi-cancer early detection test based on circulating tumor DNA analysis.[5] The underlying technology, involving multimodal analysis of cell-free DNA methylation and fragmentomics, underwent analytical validation in a case-control study and was published in the journal eLife in 2023.[7]
Clinical validation of SPOT-MAS has been reported in several independent studies, including an interim report from a prospective cohort of nearly 2,800 participants published in Cancer Investigation (2023),[8] and results from the large-scale K-DETEK prospective trial (over 9,000 asymptomatic participants) published in BMC Medicine.[9]
References
- ↑ 1.0 1.1 "Vietnam's Gene Solutions seeks $100 million from pre-IPO and 2026 listing". Reuters. November 19, 2025.
- ↑ 2.0 2.1 2.2 2.3 "Gene Solutions: How an initially risky investment became one of Vietnam's first successful biotechnology companies..." Mekong Capital. 2024.
- ↑ 3.0 3.1 "Gene Solutions secures $21 million to facilitate expansion in Southeast Asia". Vietnam Investment Review. September 21, 2023.
- ↑ 4.0 4.1 "Mekong Enterprise Fund IV completed an investment of US$15 million in Gene Solutions". Mekong Capital. October 5, 2021.
- ↑ 5.0 5.1 5.2 "Mekong Enterprise Fund IV made a Series B investment in Gene Solutions to support its expansion plan in Southeast Asia". Mekong Capital. September 20, 2023.
- ↑ "Singapore-based startup Gene Solutions to introduce smart blood test for lung screening in early 2025". BioSpectrum Asia. February 5, 2025.
- ↑ Nguyen, Trong Hieu; et al. (October 11, 2023). "Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization". eLife. 12. doi:10.7554/eLife.89083. Unknown parameter
|article-number=ignored (help) - ↑ Nguyen THH; et al. (2023). "Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants". Cancer Investigation. 41 (3): 232–248. doi:10.1080/07357907.2023.2173773. PMID 36719061 Check
|pmid=value (help). - ↑ "Vietnam's Gene Solutions Looks to Expand MCED Test Market After Strong Validation Data". GenomeWeb. February 19, 2025.
This article "Gene Solutions" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Gene Solutions. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
